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Introduction: 
 
Ambulatory care pharmacy focuses on direct interaction with patients to reconcile medication 
lists and optimize pharmacotherapy. Ambulatory care places a strong emphasis on patient 
education and self-management to promote health and wellness. Pharmacists in this field manage 
triage, referrals, and coordination of care to enhance transition of care processes. Ambulatory 
care pharmacists save time for physicians, improve access to care, and enhance economic and 
clinical outcomes. Opportunities for pharmacy involvement in the outpatient setting include 
improving medication safety and refining medication therapy for asthma, kidney disease, 
diabetes, and cardiovascular disease. Ambulatory care pharmacy services also focus on 
preventative care, medication therapy management, and lessening healthcare disparities. 
Specialty pharmacy residency and fellowship training promotes the advancement of clinical 
practice and research in ambulatory care pharmacy services.1 
 
Clinical Pharmacist Practitioners (CPPs) receive designation from the North Carolina Medical 
Board and North Carolina Board of Pharmacy to prescribe medications and order laboratory tests 
in the care of patients under the supervision or direction of a licensed physician. CPPs must have 
either (a) completed a Board of Pharmaceutical Specialties (BPS) or Geriatric Certification or 
American Society of Health-Systems Pharmacists (ASHP) accredited residency program plus 
have clinical experience for two years or (b) earned a Doctor of Pharmacy degree plus have 
clinical experience for three years plus have completed a Certificate Program or (c) earned a 
Bachelor of Science degree plus have clinical experience for five years plus have complication 
two certificate programs.2 
 
There are a total of 29.1 million patients diagnosed and undiagnosed with diabetes. Of these 
patients, 28% are left undiagnosed emphasizing that greater medical attention is needed. 
Although 37% of the US population has pre-diabetes, healthcare professionals can help delay the 
progression to diabetes.3 From 1994 to 2010 among adults 18 years or older, the proportion of 
diagnosed diabetes was age-adjusted showing that diabetes has become more prevalent across 
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the country.4 With more patients diagnosed with diabetes, the demand for healthcare is 
increasing, but the physician-patient ratio of 2.4 physicians per 1000 patients has been consistent 
from 1995 to 2012.5 Diabetes is a complex disease targeting many different organs, such as the 
liver, pancreas, fat, muscle, and brain. Close medical attention is warranted to prevent 
progression to irreversible complications. With approximately 40 different medications to treat 
diabetes, there is a great demand for skilled healthcare professionals.6 In the United Kingdom 
Prospective Diabetes Study (UKPDS), glyburide and metformin decreased glycated hemoglobin 
(A1c) for only 1-2 years with a subsequent increase thereafter, suggesting that patients need to be 
seen long-term and frequently by practitioners to manage their diabetes.7  
 
Pharmacists can play a significant role in identifying and screening high-risk patients, assessing 
health status and adherence to standards of care, monitoring outcomes, educating and 
empowering patients, and referring patients to specific healthcare professionals.8 A randomized, 
controlled trial of veteran affairs patients (n=99) with diabetes was performed to assess the 
clinical outcomes of monthly pharmacy appointments versus usual care for six months.  Patients 
in the intervention group achieved the A1c goal of < 7% and the systolic blood pressure (SBP) 
goal of < 130 mmHg at rates significantly lower than the usual care arm. There were no 
significant differences between groups with low-density lipoprotein (LDL).9 Our study aims to 
assess the clinical impact one pharmacy visit has on patients with type 2 diabetes mellitus 






The study was conducted as a retrospective pre-post study design comparing clinical outcomes 
before and after at least one CPP visit in patients with type 2 diabetes mellitus at the Family 
Medicine Center. Data was extracted from October 2012 through March 2014 on the WebCIS 
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electronic health record. The University of North Carolina (UNC) at Chapel Hill Institutional 




Patients with type 2 diabetes and at least one visit with a CPP at the Family Medicine Center 
from October 2012 through March 2014 were included in the study. Patients with gestational 




Demographics including age, sex, body mass index (BMI), weight, A1c, LDL, SBP, diastolic 
blood pressure (DBP), and diabetes-related medications were collected and assessed with 
descriptive statistics. Baseline was defined as the most recent value before or during the CPP 
visit compared to available data following the CPP visit. Follow-up was defined as the 
subsequent visits with the CPP after the first baseline visit. Changes in A1c, blood pressure, and 
LDL from baseline were used to detect the clinical efficacy of CPP interventions. The primary 
endpoint was defined as the mean change in A1c from baseline to the follow-up visits. The 
secondary endpoints assessed the change from baseline to follow-up, which included the 
percentage of patients with A1c < 7% and < 8%, the mean change in blood pressure, the 
percentage of patients with blood pressure readings < 130/80 mmHg and < 140/80 mmHg, and 
the percentage of patients with LDL < 100 mg/dL and 70mg/dL. The study also examined 
quality healthcare indicators, such as the frequency of retinal and foot exams, pneumococcal and 
influenza vaccines, and albumin/creatinine and aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) draws. Two-tailed paired t-tests, chi-squared tests, and Fisher’s exact 
tests with the alpha value set to 0.05 were used to evaluate the change in the above clinical 






A total of 105 patients were assessed in the study. The study population included 56.2% women 
(n=59) with a mean age of 59.0±10.2 years old and a mean A1c of 9.2%+2.5%. The baseline 
characteristics of the sample were recorded in Table 1. Table 2 demonstrates that there was a 
statistically significant difference in the primary outcome of A1c at baseline versus the first 
follow-up visit (9.2% vs 7.91%, -1.36% 95% CI (-1.83% to -0.89%), p<0.0001) and at baseline 
versus the second follow-up visit (9.2% vs 7.64%, -1.45% 95% CI (-2.10% to -0.80%), 
p<0.0001). When compared to the percentage of patients with A1c < 7% at baseline (19.0%), 
there were a greater percentage of patients with A1c < 7% at the first and second follow-up, 
26.4% and 33.3%, respectively. The percentage of patients with A1c < 8% increases over time 
from baseline to the first follow-up and to the second follow-up visit (36.2%, 57.0%, and 66.7%, 
respectively). Blood pressure goals varied throughout the study as the American Diabetes 
Association changed the target levels from <130/80 mmHg to <140/80 mmHg in 2013.10 As 
shown in Table 3, there was a statistically significant change in systolic blood pressure (-5.1 
mmHg, p<0.0118), but not in diastolic blood pressure (-1.6 mmHg, p<0.1958) from baseline to 
the first follow-up visit. With the targets of <130/80 mmHg and <140/80 mmHg, 38.6% and 
45.8% of patients met the blood pressure goals at the first follow-up visit, respectively. This was 
greater than the baseline percentages of 31.4% and 37.1%, respectively. Table 4 depicts that 
there was a greater percentage of patients that met LDL targets at the first follow-up when 
compared to baseline data. Secondary endpoint quality indicators revealed how frequently the 
medical team performed retinal (79.1%) and foot exams (67.6%), pneumococcal (52.4%) and 
influenza vaccines (78.1%), albumin/creatinine draws (75.0%), and AST or ALT draws (83.2%) 







Table 1. Baseline Patient Characteristics  
 
N = 105 
Age, Years + SD 59.0±10.2  
Female, n (%) 59.0 (56.2)  
Weight, Kg + SD 95.0±22.7  
BMI, Kg/m2 + SD 32.8±8.0  
Encounters, Visits 2.4±3.9  
>2 Encounters, n (%) 44.0 (39.1)  
A1c + SD 9.2+2.5  
SBP, mmHg + SD (n=104) 135.7+18.0  
DBP, mmHg + SD (n=104) 79.4+10.0  
LDL, mg/dL + SD (n=95) 108.3+39.4  
Aspirin with indication, n (%) 70.0 (66.7) 
ACEI/ARB with indication, n (%) 70.0 (66.7) 
Statin with indication, n (%) 67.0 (63.8) 
Oral/non-insulin injectable monotherapy for T2DM, n (%) 20.0 (19.1) 
Oral/non-insulin injectable combination for T2DM, n (%) 17.0 (16.2) 







Table 2. Primary Endpoint: A1c 
 
N=105 
 Baseline A1c + SD 9.2+2.5  
1st Follow-up A1c + SD (n=85) 7.9+1.7  
Change from baseline to 1st follow-up A1c  -1.4+2.2; 95% CI (-1.8 to -0.9), p<0.0001 
2nd Follow-up A1c + SD (N=36) 7.6+1.5  
Change from baseline to 2nd follow-up A1c -1.5+1.9; 95% CI (-2.1 to -0.8), p<0.0001 
 
Table 3. Secondary Endpoint: Blood Pressure 
SBP from baseline to the 1st follow-up visit, mean 
change+SD, p-value 
-5.1+17.9, p<0.01 
DBP from baseline to the 1st follow-up visit, mean 
change+SD, p-value 
-1.6+10.9, p<0.2 
Blood pressure <130/80 at baseline, n (%) 33.0 (31.4)  
Blood pressure <130/80 at the 1st follow-up visit, n (%) 32.0 (38.6) 
Blood pressure <140/80 at baseline, n (%) 39.0 (37.1) 
Blood pressure <140/80 at the 1st follow-up visit, n(%) 38.0 (45.8) 
 
Table 4. Secondary Endpoint: LDL 
 
n (%) 
LDL<70mg/dL at baseline 11.0 (11.6) 
LDL<70mg/dL at the first follow-up visit 8.0 (21.1) 
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LDL<100mg/dL at baseline 41.0 (43.2)  




It can be a challenge for physicians to adequately address the pathophysiology and management 
of type 2 diabetes mellitus in a short patient visit. Interdisciplinary teamwork can help strengthen 
patient care surrounding diabetes.8 CPPs at UNC Family Medicine Center impact the healthcare 
of patients with diabetes immediately and directly during the visit with consultation. Although 
each patient in this study only had a mean of 2.4 visits with the CPP during the study period, 
there were still significant improvements in clinical indicators such as A1c and systolic blood 
pressure. If a CPP at the UNC Family Medicine Center sees a patient for 2 to 3 visits, the 
patient’s A1c may significantly lower, potentially reducing complications related to diabetes in 
the future. Pharmacy services at the Family Medicine Center helps ensure appropriate routine 
monitoring including retinal and foot exams, urine/creatinine and AST or ALT draws, and 
annual vaccinations. CPPs at other institutions may provide similar benefits in patients with type 
2 diabetes mellitus.  
 
Results in this study were similar to those seen in previous trials assessing the impact of 
pharmacy services on clinical outcomes in patients with type 2 diabetes mellitus. A1c and 
systolic blood pressure were significantly lowered in both this review and the randomized, 
controlled trial assessing monthly pharmacy appointments in veterans for 6 months. There were 
no differences in LDL between the control and intervention arms, similar to the LDL outcomes 
in our review.9 A meta-analysis of 14 randomized, controlled trials evaluating the effect of 
pharmacy programs on glycemic control in patients with diabetes found a significant reduction 
of A1c levels with the pharmacy intervention arm versus the usual care arm.11 Together the 
results of previous studies and our trial suggest that incorporating pharmacists into diabetes 
management should be strongly considered to provide clinical benefit.  
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This study had several limitations. There was a lack of information on diet and exercise goals, 
frequency of hypoglycemia, and cigarette or alcohol abuse in patients’ charts. Without this data, 
it is difficulty to distinguish how pharmacists impacted the sample population. There was also no 
assessment of the duration of type 2 diabetes mellitus in the study, which would have helped to 
separate high versus low risk patients. Other limitations include the lack of frequent A1c levels, 
no control group, and the time limit of the Honors Program. The change in blood pressure 
recommendations from the American Diabetes Association guidelines presents another 
challenge.  
 
Future studies are needed to determine if ambulatory care pharmacy is a cost effective 
intervention. In addition, future studies can include a control group that has not been seen by a 
pharmacist. Assessing diabetes medications and their effect on clinical outcomes could help 
guide practitioners at the Family Medicine Center towards which agents to use. Including patents 
from other UNC healthcare services would help to increase the sample size and provide more 
reliable results.  
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